---
title: "禮來公司高管談 Mounjaro：“我們現已在 55 個國家推出該產品，且覆蓋了所有主要市場”。"
description: "禮來公司高管談 Mounjaro：“我們現已在 55 個國家推出該產品，且覆蓋了所有主要市場”。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/263546592.md"
published_at: "2025-10-30T14:14:00.000Z"
---

# 禮來公司高管談 Mounjaro：“我們現已在 55 個國家推出該產品，且覆蓋了所有主要市場”。

禮來公司高管談 Mounjaro：“我們現已在 55 個國家推出該產品，且覆蓋了所有主要市場”。

### Related Stocks

- [LLY.US - 禮來](https://longbridge.com/zh-HK/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Eli Lilly and Company $LLY Shares Acquired by Assetmark Inc. | Assetmark Inc. increased its holdings in Eli Lilly and Company (NYSE: LLY) by 6.0% in Q3, owning 55,360 shares valued at | [Link](https://longbridge.com/zh-HK/news/275971336.md) |
| Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill | Eli Lilly (LLY) has prepared a $1.5 billion inventory of its new weight-loss pill, Orforglipron, ahead of its anticipate | [Link](https://longbridge.com/zh-HK/news/276070062.md) |
| Eli Lilly: Mirikizumab approved in China for treatment of moderate-to-severe Crohn's disease and ulcerative colitis - Co statement | Eli Lilly: Mirikizumab approved in China for treatment of moderate-to-severe Crohn's disease and ulcerative colitis - Co | [Link](https://longbridge.com/zh-HK/news/275551012.md) |
| Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients | Eli Lilly's Phase 3 LIBRETTO-432 trial for Retevmo (selpercatinib) shows significant reduction in recurrence risk for ea | [Link](https://longbridge.com/zh-HK/news/276119494.md) |
| Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study | Eli Lilly's weight-loss drug Zepbound, combined with psoriasis treatment Taltz, demonstrated significant improvements in | [Link](https://longbridge.com/zh-HK/news/276222614.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。